See what CanVECTOR members are publishing to advance the field of venous thromboembolism
Publications since 2016 that are linked to venous thromboembolism and/or anticoagulant therapy

Publications for Jameel Abdulrehman

Updated daily

Back to Member List

#	PubMedId	Deleted	Publication
	40216708	0	Makedonov I, Kapitanski L, Giai J, et al. Treatment of isolated distal deep vein thrombosis: an international survey of healthcare professionals. J Thromb Thrombolysis. 2025 Apr 11. doi: 10.1007/s11239-025-03091-5.
	39420740	0	Raslan IA, Solh Z, Kuo KHM, et al. Venous Thromboembolism in Individuals with Sickle Cell Disease: A Narrative Review. Hemoglobin. 2024 Oct 18:1-13. doi: 10.1080/03630269.2024.2371884.
	39122193	0	Galanaud JP, Krebs-Drouot L, Genty-Vermorel C, et al. Very Long-term Risk of Moderate-Severe Post-Thrombotic Syndrome after Deep Vein Thrombosis. J Thromb Haemost. 2024 Aug 7:S1538-7836(24)00438-0. doi: 10.1016/j.jtha.2024.07.020.
	38692087	0	Huroy M, Selby R, Sutradhar S, et al. Peak plasma anti-Xa direct oral anticoagulant levels after gastrointestinal surgeries: A retrospective cohort. Thromb Res. 2024 Apr 19;238:85-87. doi: 10.1016/j.thromres.2024.04.019.
	38262288	0	Abdulrehman J, Harrigan A, Simard C, et al. TRanEXamic acid to decrease Heavy Menstrual Bleeding in individuals anticoagulated for venous thromboembolism (T-REX HMB): Health care practitioner survey. Thromb Res. 2024 Jan 17;235:11-14. doi: 10.1016/j.thromres.2024.01.009.
	38171625	0	Abdulrehman J, Forte S, Tomlinson G, et al. THromboprophylaxis In Sickle Cell Disease with central venous catheters (THIS): an internal pilot randomised controlled trial protocol. BMJ Open. 2024 Jan 3;14(1):e079363. doi: 10.1136/bmjopen-2023-079363.
	37949316	0	Shaw JR, Li N, Abdulrehman J, et al. Periprocedural Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Active Cancer. J Thromb Haemost. 2023 Nov 8:S1538-7836(23)00830-9. doi: 10.1016/j.jtha.2023.10.028.
	37907305	0	Makedonov I, Kahn S, Abdulrehman J, et al. TILE pilot trial study protocol: Tinzaparin Lead-in to Prevent the Post-Thrombotic syndrome study protocol. BMJ Open. 2023 Oct 31;13(10):e064715. doi: 10.1136/bmjopen-2022-064715.
	36444228	0	Papadopoulos E, Abdulrehman J, Alibhai SMH. The Value of Performance Status in Predicting Clinical Outcomes in Patients With Cancer-Associated Pulmonary Embolism. JACC CardioOncol. 2022 Nov 15;4(4):519-521. doi: 10.1016/j.jaccao.2022.10.001. eCollection 2022 Nov.
	36122573	0	Ziemba YC, Abdulrehman J, Hollestelle MJ, et al. Diagnostic Testing for von Willebrand Disease: Trends and Insights from North American Laboratories over the Last Decade. Semin Thromb Hemost. 2022 Sep 19. doi: 10.1055/s-0042-1754332.
	35877546	0	Abdulrehman J, Elbaz C, Aziz D, et al. Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and meta-analysis. Br J Haematol. 2022 Jul 25. doi: 10.1111/bjh.18331.
	35268283	0	Forte S, De Luna G, Abdulrehman J, et al. Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study. J Clin Med. 2022 Feb 23;11(5). pii: jcm11051193. doi: 10.3390/jcm11051193.
	34996086	0	Selby R, Abdulrehman J. Antiphospholipid Antibodies and the Antiphospholipid Syndrome: From Coagulation to the Clinic. J Appl Lab Med. 2022 Jan 5;7(1):373-378. doi: 10.1093/jalm/jfab134.
	34852380	0	Makedonov I, Kahn SR, Abdulrehman J, et al. Prevention of the post thrombotic syndrome with anticoagulation: a narrative review. Thromb Haemost. 2021 Dec 1. doi: 10.1055/a-1711-1263.
	34613576	0	Kwan V, Kaplovitch E, Selby R, et al. Effectiveness and safety of the direct oral anticoagulants in non-triple positive antiphospholipid syndrome without prior arterial thromboembolism. J Thromb Thrombolysis. 2021 Oct 6. pii: 10.1007/s11239-021-02578-1. doi: 10.1007/s11239-021-02578-1.
	34518263	0	Galanaud JP, Abdulrehman J, Lazo-Langner A, et al. MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial. BMJ Open. 2021 Sep 13;11(9):e049557. doi: 10.1136/bmjopen-2021-049557.
	34455654	0	Abdulrehman J, Ziemba YC, Hsu P, et al. Diagnosis of von Willebrand disease: An assessment of the quality of testing in North American laboratories. Haemophilia. 2021 Nov;27(6):e713-e720. doi: 10.1111/hae.14397. Epub 2021 Aug 28.
	34401639	0	Abdulrehman J, Zarabi S, Elbaz C, et al. Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals. Res Pract Thromb Haemost. 2021 Aug 7;5(5):e12535. doi: 10.1002/rth2.12535. eCollection 2021 Jul.
	31668083	0	Abdulrehman J, Eikelboom JW, Siegal DM. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. Future Cardiol. 2019 Nov;15(6):395-404. doi: 10.2217/fca-2019-0038. Epub 2019 Oct 31.
	27931012	0	Garcia-Horton A, Kovacs MJ, Abdulrehman J, et al. Impact of thrombophilia screening on venous thromboembolism management practices. Thromb Res. 2017 Jan;149:76-80. doi: 10.1016/j.thromres.2016.11.023. Epub 2016 Dec 1.